TPST experienced severe financial deterioration with cash declining 75% to just $7.7M while simultaneously executing a reverse stock split that reduced share count from 45.4M to 14.3M shares.
The dramatic cash burn combined with a reverse stock split signals acute financial distress and potential going concern issues for this clinical-stage biotech company. While the company pivoted strategy by acquiring CAR-T assets in February 2026, the severely constrained cash position raises immediate questions about their ability to fund operations and clinical development without emergency financing.
TPST's financial position deteriorated dramatically with cash and equivalents plummeting 75% from $30.3M to $7.7M, while total assets declined 59% and stockholders' equity fell 65%. Although net losses improved 37% to -$26.3M due to reduced SG&A expenses (-44%), and revenue declined 55%, the company's cash runway appears critically short for a clinical-stage biotech requiring substantial R&D funding. The massive reduction in current assets (-74%) alongside the reverse stock split indicates severe liquidity constraints that could threaten ongoing operations.
Current liabilities reduced — improved short-term financial position and working capital health.
Cash declined 74.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Current assets declined 73.7% — monitor working capital adequacy and short-term liquidity.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Total assets contracted 59.2% — asset sales, write-downs, or balance sheet optimization underway.
Revenue declined 54.8% — significant demand weakness or market share loss warrants investigation.
Liabilities reduced 54.1% — deleveraging improves balance sheet strength and financial flexibility.
SG&A reduced 43.6% — improved cost efficiency or headcount reduction improving operating margins.
Debt reduced 39% — deleveraging strengthens balance sheet and reduces financial risk.
Net income grew 37.2% — bottom-line growth signals improving overall business health.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →